TERN
Company Description
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.00M | 0 | 0 | 0 |
| Net Income | (96.21M) | (88.85M) | (90.21M) | (60.34M) | (50.16M) | (29.35M) | (68.82M) | (17.71M) |
| EPS | -1.03 | -1.12 | -1.27 | -1.67 | -1.98 | -1.61 | -2.74 | -0.74 |
| Free Cash Flow | (82.18M) | (70.06M) | (67.44M) | (49.38M) | (42.17M) | (30.39M) | (67.12M) | (18.32M) |
| FCF / Share | -0.88 | -0.88 | -0.95 | -1.37 | -1.67 | -1.21 | -2.67 | -0.76 |
| Operating CF | (82.18M) | (70.02M) | (67.39M) | (49.11M) | (41.83M) | (29.81M) | (66.22M) | (18.07M) |
| Total Assets | 1.03B | 363.93M | 268.52M | 287.03M | 168.07M | 92.29M | 23.90M | 89.07M |
| Total Debt | 919,000 | 1.35M | 603,000 | 1.21M | 0 | 12.88M | 0 | 0 |
| Cash & Equiv | 524.75M | 161.44M | 79.93M | 143.24M | 47.70M | 74.85M | 12.33M | 82.52M |
| Book Value | 1.01B | 345.87M | 255.37M | 276.94M | 160.30M | 68.59M | 4.21M | 72.23M |
| Return on Equity | -0.10 | -0.26 | -0.35 | -0.22 | -0.31 | -0.43 | -16.36 | -0.25 |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.57M) | (24.64M) | (24.09M) | (23.91M) | (21.80M) | (21.95M) | (22.74M) | (22.37M) | (21.02M) | (29.77M) | (17.90M) | (21.53M) |
| EPS | -0.24 | -0.27 | -0.26 | -0.26 | -0.24 | -0.28 | -0.31 | -0.30 | -0.29 | -0.42 | -0.25 | -0.31 |
| Free Cash Flow | (19.08M) | (19.77M) | (18.88M) | (24.45M) | (14.58M) | (16.45M) | (16.19M) | (22.83M) | (19.36M) | (20.71M) | (12.99M) | (14.38M) |
| FCF / Share | -0.20 | -0.22 | -0.21 | -0.27 | -0.16 | -0.21 | -0.22 | -0.31 | -0.27 | -0.29 | -0.18 | -0.21 |
| Operating CF | (19.08M) | (19.77M) | (18.88M) | (24.45M) | (14.58M) | (16.45M) | (16.18M) | (22.80M) | (19.32M) | (20.70M) | (12.99M) | (14.38M) |
| Total Assets | 1.03B | 301.65M | 320.42M | 339.31M | 363.93M | 378.23M | 230.88M | 246.77M | 268.52M | 271.69M | 289.70M | 301.29M |
| Total Debt | 919,000 | 1.03M | 1.13M | 1.24M | 1.35M | 1.30M | 249,000 | 427,000 | 603,000 | 770,000 | 876,000 | 1.04M |
| Cash & Equiv | 524.75M | 150.70M | 145.97M | 139.02M | 161.44M | 270.14M | 91.50M | 65.10M | 79.93M | 37.89M | 80.92M | 184.35M |
| Book Value | 1.01B | 284.07M | 305.23M | 326.04M | 345.87M | 364.47M | 218.68M | 236.72M | 255.37M | 258.43M | 274.15M | 287.68M |
| Return on Equity | -0.02 | -0.09 | -0.08 | -0.07 | -0.06 | -0.06 | -0.10 | -0.09 | -0.08 | -0.12 | -0.07 | -0.07 |
